Independent adipogenic and contractile properties of fibroblasts in Graves' orbitopathy: An in vitro model for the evaluation of treatments

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Li, He ^a   Fitchett, Caroline ^a   Kozdon, Katarzyna ^a   Jayaram, Hari ^a   Rose, Geoffrey E ^a,b   Bailly, Maryse ^a   Ezra, Daniel G ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1;

ADIPOCYTE; ADIPOGENESIS; ADULT; AGED; ARTICLE; CELL CONTRACTION; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCRINE OPHTHALMOPATHY; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MIDDLE AGED; PHENOTYPE; PROGRAM EFFICACY; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; EXTRACELLULAR MATRIX; METABOLISM; PATHOLOGY; PRESSURE;

ADIPOGENESIS; AGED; ANTIGENS, THY-1; CELLS, CULTURED; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; PRESSURE;

EID: 84899689800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095586     Document Type: Article

References (49)

1. Garrity JA, Bahn RS (2006) Pathogenesis of Graves Ophthalmopathy: Implications for Prediction, Prevention, and Treatment. Am J Ophthalmol 142: 147-153.e2. doi:10.1016/j.ajo.2006.02.047.
2. Sisson JC, Spaugh BI, Vanderburg JA (1970) Functional aspects of fibroblasts derived from the retrobulbar tissue of man. Exp Eye Res 10: 201-206.
3. Kumar S (2004) Evidence for Enhanced Adipogenesis in the Orbits of Patients with Graves' Ophthalmopathy. Journal of Clinical Endocrinology & Metabolism 89: 930-935. doi:10.1210/jc.2003-031427.
4. Zhang L, Grennan-Jones F, Lane C, Rees DA, Dayan CM, et al. (2012) Adipose Tissue Depot-Specific Differences in the Regulation of Hyaluronan Production of Relevance to Graves' Orbitopathy. J Clin Endocrinol Metab 97: 653-662. doi:10.1210/jc.2011-1299.
5. Khoo TK, Coenen MJ, Schiefer AR, Kumar S, Bahn RS (2008) Evidence for enhanced Thy-1 (CD90) expression in orbital fibroblasts of patients with Graves' ophthalmopathy. Thyroid 18: 1291-1296. doi:10.1089/thy.2008.0255.
6. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, et al. (2001) Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 87: 385-392.
7. Smith TJ (2010) Potential role for bone marrow-derived fibrocytes in the orbital fibroblast heterogeneity associated with thyroid-associated ophthalmopathy. Clinical & Experimental Immunology 162: 24-31. doi:10.1111/j.1365-2249.2010.04219.x.
8. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, et al. (2012) Nuclear Targeting of IGF-1 Receptor in Orbital Fibroblasts from Graves' Disease: Apparent Role of ADAM17. PLoS ONE 7: e34173. doi:10.1371/journal.pone.0034173. g007.
9. Smith TJ (2004) Immunoglobulins from Patients with Graves' Disease Induce Hyaluronan Synthesis in Their Orbital Fibroblasts through the Self-Antigen, Insulin-Like Growth Factor-I Receptor. J Clin Endocrinol Metab 89: 5076-5080. doi:10.1210/jc.2004-0716.
10. Koumas L, Smith TJ, Feldon S, Blumberg N, Phipps RP (2003) Thy-1 Expression in Human Fibroblast Subsets Defines Myofibroblastic or Lipofibroblastic Phenotypes. The American Journal of Pathology 163: 1291-1300. doi:10.1016/S0002-9440(10)63488-8. (Pubitemid 37175078)
11. Ezra DG, Beaconsfield M, Collin R (2009) Surgical anatomy of the upper eyelid: old controversies, new concepts. Ex Rev Op 4: 47-57. doi:10.1586/17469899.4.1.47.
12. Riemann CD, Foster JA, Kosmorsky GS (1999) Direct orbital manometry in healthy patients. Ophthalmic Plastic and Reconstructive Surgery 15: 121-125. (Pubitemid 29481882)
13. Berthout A, Vignal C, Jacomet PV, Galatoire O, Morax S (2010) Intraorbital pressure measured before, during, and after surgical decompression in Graves' orbitopathy. J FR Ophthalmol 33: 623-629.
14. Discher DE, Janmey P, Wang Y-L (2005) Tissue cells feel and respond to the stiffness of their substrate. Science 310: 1139-1143. doi:10.1126/science. 1116995. (Pubitemid 41681732)
15. Chen WLK, Simmons CA (2011) Lessons from (patho)physiological tissue stiffness and their implications for drug screening, drug delivery and regenerative medicine. Adv Drug Deliv Rev 63: 269-276. doi:10.1016/j.addr.2011. 01.004.
16. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS (2004) Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev Cell 6: 483-495. (Pubitemid 38456178)
17. Ezra DG, Ellis JS, Beaconsfield M, Collin R, Bailly M (2010) Changes in fibroblast mechanostat set point and mechanosensitivity: an adaptive response to mechanical stress in floppy eyelid syndrome. Invest Ophthalmol Vis Sci 51: 3853-3863. doi:10.1167/iovs.09-4724.
18. Peirson SN (2003) Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Research 31: 73e-73. doi:10.1093/nar/gng073.
19. Martin-Martin B, Tovell V, Dahlmann-Noor AH, Khaw PT, Bailly M (2011) The effect of MMP inhibitor GM6001 on early fibroblast-mediated collagen matrix contraction is correlated to a decrease in cell protrusive activity. European Journal of Cell Biology 90: 26-36. doi:10.1016/j.ejcb.2010.09.008.
20. Tovell VE, Chau CY, Khaw PT, Bailly M (2012) Rac1 Inhibition Prevents Tissue Contraction and MMP Mediated Matrix Remodeling in the Conjunctiva. Invest Ophthalmol Vis Sci 53: 4682-4691. doi:10.1167/iovs.11-8577.
21. Bartalena L, Tanda ML, Piantanida E, Lai A (2003) Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 19: 155-163. (Pubitemid 38175119)
22. Hondur A, Konuk O, Dincel AS, Bilgihan A, Unal M, et al. (2008) Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves' ophthalmopathy. Curr Eye Res 33: 421-427. doi:10.1080/02713680802123532. (Pubitemid 351998840)
23. Zarković M (2012) The role of oxidative stress on the pathogenesis of graves' disease. J Thyroid Res 2012: 302537. doi:10.1155/2012/302537.
24. McGee KM, Vartiainen MK, Khaw PT, Treisman R, Bailly M (2011) Nuclear transport of the serum response factor coactivator MRTF-A is downregulated at tensional homeostasis. EMBO Rep 12: 963-970. doi:10.1038/embor.2011.141.
25. van Steensel L, Paridaens D, Dingjan GM, van Daele PLA, van Hagen PM, et al. (2010) Platelet-Derived Growth Factor-BB: A Stimulus for Cytokine Production by Orbital Fibroblasts in Graves' Ophthalmopathy. Invest Ophthalmol Vis Sci 51: 1002-1007. doi:10.1167/iovs.09-4338.
26. van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PLA, et al. (2009) Imatinib Mesylate and AMN107 Inhibit PDGF-Signaling in Orbital Fibroblasts: A Potential Treatment for Graves' Ophthalmopathy. Invest Ophthalmol Vis Sci 50: 3091-3098. doi:10.1167/iovs.08-2443.
27. Sun Y, Ma Y-C, Huang J, Chen KY, McGarrigle DK, et al. (2005) Requirement of SRC-family tyrosine kinases in fat accumulation. Biochemistry 44: 14455-14462. doi:10.1021/bi0509090. (Pubitemid 41567453)
28. Mastick CC, Saltiel AR (1997) Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J Biol Chem 272: 20706-20714. (Pubitemid 27355635)
29. Rege TA, Pallero MA, Gomez C, Grenett HE, Murphy-Ullrich JE, et al. (2006) Thy-1, via its GPI anchor, modulates Src family kinase and focal adhesion kinase phosphorylation and subcellular localization, and fibroblast migration, in response to thrombospondin-1/hep I. Exp Cell Res 312: 3752-3767. doi:10.1016/j.yexcr.2006.07.029. (Pubitemid 44633878)
30. Pei Y, Sherry DM, McDermott AM (2004) Thy-1 distinguishes human corneal fibroblasts and myofibroblasts from keratocytes. Exp Eye Res 79: 705-712. doi:10.1016/j.exer.2004.08.002. (Pubitemid 39419488)
31. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, et al. (2012) Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17. PLoS ONE 7: e34173. doi:10.1371/journal.pone.0034173.
32. Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS (2010) Immunopathogenesis of Thyroid Eye Disease: Emerging Paradigms. Survey of Ophthalmology 55: 215-226. doi:10.1016/j.survophthal.2009.06.009.
33. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS (2012) A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab 97: 1681-1687. doi:10.1210/jc.2011-2890.
34. Crisp M, Starkey KJ, Lane C, Ham J, Ludgate M (2000) Adipogenesis in thyroid eye disease. Invest Ophthalmol Vis Sci 41: 3249-3255.
35. Baker BM, Chen CS (2012) Deconstructing the third dimension - how 3D culture microenvironments alter cellular cues. Journal of cell science.
36. Cukierman E (2001) Taking Cell-Matrix Adhesions to the Third Dimension. Science 294: 1708-1712. doi:10.1126/science.1064829.
37. Oh S-R, Tung JD, Priel A, Levi L, Granet DB, et al. (2013) Reduction of Orbital Inflammation following Decompression for Thyroid-Related Orbitopathy. BioMed Research International 2013: 1-6. doi:10.1016/j.ophtha.2005.10.060.
38. Huang C, Ogawa R (2012) Fibroproliferative disorders and their mechanobiology. Connect Tissue Res 53: 187-196. doi:10.3109/03008207.2011. 642035.
39. Stacey DH, Hanson SE, Lahvis G, Gutowski KA, Masters KS (2009) In vitro adipogenic differentiation of preadipocytes varies with differentiation stimulus, culture dimensionality, and scaffold composition. Tissue Eng Part A 15: 3389-3399. doi:10.1089/ten.TEA.2008.0293.
40. Koumas L, Smith TJ, Phipps RP (2002) Fibroblast subsets in the human orbit: Thy-1+ and Thy-1- subpopulations exhibit distinct phenotypes. Eur J Immunol 32: 477-485. doi:10.1002/1521-4141(200202)32:2〈477::AID- IMMU477〉3.0.CO;2-U.
41. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, et al. (2012) Nuclear Targeting of IGF-1 Receptor in Orbital Fibroblasts from Graves' Disease: Apparent Role of ADAM17. PLoS ONE 7: e34173. doi:10.1371/journal.pone.0034173. g007.
42. Smith TJ (2003) The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 36: 409-415.
43. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170: 6348-6354. (Pubitemid 36682621)
44. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, et al. (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 181: 4397-4405.
45. www.clinicaltrials.gov (n.d.) www.clinicaltrials.gov. Available: http://www.clinicaltrials.gov.Accessed 2013 Aug 4.
46. Kang SM, Lee SY (2013) Effects of PDGF-BB and b-FGF on the production of cytokines, hyaluronic acid and the proliferation of orbital fibroblasts in thyroid ophthalmopathy. Mol Cell Toxicol 9: 195-202. doi:10.1007/s13273-013- 0024-1.
47. Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, et al. (2011) The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells. PLoS ONE 6: e28555. doi:10.1371/journal.pone.0028555.
48. Zhao SX, Tsui S, Cheung A, Douglas RS, Smith TJ, et al. (2011) Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA. Journal of Endocrinology 210: 369-377. doi:10.1530/JOE-11-0162.
49. Moshkelgosha S, So P-W, Deasy N, Diaz-Cano S, Banga JP (2013) Cutting Edge: Retrobulbar Inflammation, Adipogenesis, and Acute Orbital Congestion in a Preclinical Female Mouse Model of Graves' Orbitopathy Induced by Thyrotropin Receptor Plasmid-in Vivo Electroporation. Endocrinology 154: 3008-3015. doi:10.1210/en.2013-1576.